INSMED Inc 4

Chair and CEO William Lewis exercised 10,700 Insmed Inc. stock options and sold 10,700 shares of common stock on July 23, 2026 under a Rule 10b5-1 trading plan.

On July 23, 2026, Insmed Inc. Chair and CEO William Lewis exercised two tranches of stock options—6,260 options at an exercise price of $30.46 and 4,440 options at $17.16—acquiring a total of 10,700 shares of Insmed common stock, and on the same day sold 4,828 shares at a weighted average price of $105.62 and 5,872 shares at a weighted average price of $106.43 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. The option exercises were reported as acquisitions of common stock, lifting his directly held common stock to 269,758 shares before the sales; after selling an aggregate 10,700 shares, his direct holdings stood at 259,058 shares, with an additional 233,924 shares held indirectly in a trust. Using the reported sale prices as a proxy for market value, the gross value of the options exercised was approximately $1.15 million while the gross proceeds from the sales were approximately $1.14 million, implying these transactions were largely a cashless monetization of vested options rather than an outright directional change in his equity exposure, and his remaining direct stake is worth roughly $27.6 million at about $106 per share, excluding the substantial indirect trust holdings.

Filing Facts

CIK

1104506

Ticker

INSM

Form

4

Source Type

fda

Accession

0001402051-26-000042

Alert Tier

6